Vantis Vascular Announces $10M Series B-1 Financing to Commercialize CrossFAST™ Integrated Microcatheter Delivery System for Complex PCI Procedures

Dec 17, 2024 17:20 CST Updated 17:20

Vantis Vascular

Developer of Vascular Interventional Therapy Technology

December 12, 2024Vantis Vascular Announces Completion of $10 Million (Approx. RMB 73 Million) Series B-1 Preferred Financing.The funds will be used to launch itsCrossFAST™ Integrated Microcatheter Advanced Delivery SystemIn the United States, the commercialization of this system can be used for complex and high-riskPercutaneous Coronary Intervention(Percutaneous Coronary Intervention, PCI) surgery.

# Product Introduction

Research and Development Background

PercutaneousPercutaneous Coronary Intervention (PCI)It is an effective treatment method that can dilate, narrow, or block coronary arteries, thereby alleviating the angina symptoms they cause. During some complex PCI procedures, it is common to encounter situations where microcatheters, guidewires, and therapeutic devices (such as drug-coated balloons, stents, etc.) cannot be successfully delivered to the lesion site.Guidance ExtensionCatheter (Guide Extension Catheter)Can assist in providing good support for microcatheters and microwires to pass through stenotic calcified lesions, improve coaxiality to enhance the operator's push performance of the device, and provide a smooth channel for the delivery of special instruments to successfully deliver therapeutic devices to the lesion site.

Previously, the guiding extension catheters in the Chinese market were mainly provided by foreign companies such as Medtronic and Teleflex. Now, some domestic companies in China are also able to provide guiding extension catheters. However, whether from foreign or domestic sources, the guiding extension catheters haveTwo Major Issues — Insufficient Pushability During Use and Risk of Vascular Injury During DeliveryVantis Vascular identified issues with traditional guidewriting extension catheters and decided to develop a new type of guidewriting extension catheter that addresses these two drawbacks. Thus, the CrossFAST Guidewriting Extension Catheter was born.

Product Introduction

The CrossFAST System is the first and only advanced delivery system featuring a dual-monorail microcatheter specifically designed for complex coronary and peripheral interventions.The DepartmentThe system adopts an integrated microcatheter and seamless transition to reduce the risk of adverse events during catheter delivery.CrossFAST System Adopts DuoPRO™ Interlocking TechnologyThis is a novel mechanism that couples a microcatheter with an external delivery catheter, allowing the system to advance as a single unit, thereby enhancing pushability and efficient navigation. This breakthrough overcomes a significant limitation of guiding extension catheters, particularly reducing risks during complex, high-risk procedures.

CrossFAST mainly consists of three parts:

Seamless Profile：The use of DuoPro interlock technology allows for quick, easy, and smooth navigation through tortuous, calcified, and even stented lesion vessels.

Inner Microcatheter：Its microcatheter tip adopts a non-traumatic tip design and a seamless transition area design, which can prevent vascular injury;

Outer Delivery Catheter：Its flared central lumen entrance design simplifies stent insertion and advancement, allowing even more rigid shockwave balloon catheters to be delivered smoothly.

Product Features:

DuoPro Interlock TechnologyCrossFast adopts Vantis' unique DuoPro interlocking technology, enhancing control and flexibility, allowing it to better navigate calcified and complex vascular anatomies.
Smooth Push Capability: This catheter is designed with a low profile and tapered shape, allowing it to smoothly navigate through complex and calcified arteries, eliminating the need for "crawling" in calcified segments and enhancing overall navigation efficiency.
Microcatheter IntegrationCrossFast is the first integrated microcatheter guiding extension catheter, allowing both inner and outer catheters to advance as a single unit, thereby enhancing the delivery capability of therapeutic devices.
Reduce the Risk of Injury: Its non-invasive microcatheter tip and seamless transition design help prevent vascular tearing and damage, ensuring safety during the surgical procedure.
Applicable to Complex Cases: CrossFast is particularly suitable for handling narrow, tortuous, or severely calcified vessels, offering greater convenience and effectiveness for interventional treatments.

# About Vantis Vascular

Vantis Vascular, Inc. is a medical technology company dedicated to revolutionizing vascular interventional therapies, focusing on innovative and patient-centered solutions, committed to advancing the field of interventional cardiology and improving treatment outcomes for patients worldwide.

In May 2024, Vantis Vascular announced the successful completion of a $5 million SAFE (Simple Agreement for Future Equity) financing round, which is convertible in Vantis’ future Series C preferred round. This marks an important milestone in the company’s journey to advance the field of interventional cardiology and improve patient outcomes.

In October 2024, Vantis Vascular announced that its CrossFast Integrated Microcatheter Guiding Extension System received FDA 510(k) clearance.

# List of Award-Winning Medical Device Companies

Global Surgical Robotics Industry Awards 2024

Global Medical Technology Innovation Award 2024

Global MedTech Newcomer Award 2024

Global Innovation Medical Device Award 2024

# Overseas Large Medical Device Manufacturers

Medtronic｜Johnson & Johnson MedTech｜Abbott｜Siemens Healthineers｜Philips Medical｜Stryker｜GE Healthcare｜Boston Scientific｜ESSILOR｜Alcon｜Carl Zeiss Medical

#EnMajor Medical Device Manufacturers in China

Mindray Medical｜Lepu Medical|MicroPort Medical｜Weigao Group|United Imaging Healthcare